logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 865 2352511, +7 865 2353229.

E-mail
medvestnik@stgmu.ru

Pharmacogenetic testing on warfarin and clopidorgel in conditions of a multiprofile hospital

[Internal diseases]
Galina Ketova; Valeriya Barysheva;

In the study 236 patients was included. Decoding of the genotypes was carried out with kits of reagent for determining genetic polymorphisms associated with the metabolism of warfarin or clopidogrel with detection PCR results in real-time; and melting curve analysis, qualitative analysis («NPO DNA-Technology», Russia). The age mean age of the patients was 57.5±12.01 years. Gender differences included 54.6 % male. Clopidogrel sensitivity is influenced by several genetic polymorphisms: АВСВ1: CC – 19.1 %, CT – 42.6 %, TT – 31.2 %. CYP2C19*2: GG – 78.7 %, AA – 2.1 %. CYP2C19*3: GG – 100 %. CYP2C19*17: CC – 57.4 %, CT – 36.9 %, TT – 5.7 %. Allelic variants:*1/*1 – 39.7 %, *1/*2 – 15.6 %, *2/*17 – 4.3 %, *2/*2 – 2.1 *1/*17 – 32.6 %, *17/*17 – 5.7 %. Thus, the prevalence of genotypes associated with resistance to clopidogrel in the studied population is 22.0 %. The frequency of genotypes associated with high sensitivity to warfarin in the studied population was: CYP2C9*1/*2 – 17.9 %, CYP2C9*1/*3 – 13.7 %, CYP2C9 *2/*3 – 2.1 %, AA VKORC1 – 21.1 %.

Download

References:
1. Buzoianu A., Trifa A., Mureşanu D., Crişan S. Analysis ofCYP2C9*2,CYP2C9*3andVKORC1-1639 G>A polymorphisms in a population from South-Eastern Europe. Journal of Cellular and Molecular Medicine. 2012;16(12):2919-2924. doi: 10.1111/j.1582-4934.2012.01606.x
2. Cha P., Mushiroda T., Takahashi A., Kubo M., Minami S. [et al.] Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Human Molecular Genetics. 2010;19(23):4735-4744. doi:10.1093/hmg/ddq389
3. Furuta T., Sugimoto M., Shirai N. Individualized Therapy for Gastroesophageal Reflux Disease. Molecular Diagnosis & Therapy. 2012;16(4):223-234. doi:10.2165/11634960-000000000-00000
4. Hulot J. Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244-2247. doi: 10.1182/blood-2006-04-013052
5. Johnson M., Richard C., Bogdan R., Kidd R. Warfarin Dosing in a Patient withCYP2C9*3*3andVKORC1-1639 AAGenotypes. Case Reports in Genetics 2014:1-4. doi: 10.1155/2014/413743
6. Karaźniewicz-Łada M., Danielak D., Rubiś B., Burchardt P., Komosa, A. [et al.] Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. Journal of Clinical Pharmacy and Therapeutics. 2014;40(2):226-231. doi: 10.1111/jcpt.12236
7. Militaru F. C., Vesa S. C., Pop T. R. [et al.] Pharmacogenetics aspects of oral anticoagulants therapy. J. Med. Life. 2015;8 (2):171-175.
8. Sibbing D., Koch W., Gebhard D., Schuster T., Braun S. [et al.] A. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation. 2010;121(4):512-518. doi: 10.1161/CIRCULATIONAHA.109.885194
9. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E. [et al.] Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009;360:363-375. doi: 10.1056/NEJMoa0808227
10. Sychev D., Denisenko N., Sizova Z., Grachev A., Velikolug K. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmacogenomics and Personalized Medicine. 2015. doi: 10.2147/PGPM.S78986
11. Taubert D., Vvonbeckerath N., Grimberg G., Lazar A., Jung N. [et al.] Impact of P-glycoprotein on clopidogrel absorption. Clinical Pharmacology & Therapeutics. 2006;80(5):486-501. doi: 10.1016/j.clpt.2006.07.007
12. Yang J., Lin C. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy ofHelicobacter pyloriinfection. Expert Opinion on Drug Metabolism & Toxicology.2009;6(1):29-41. doi: 10.1517/17425250903386251

Keywords: pharmacogenetics, pharmacogenetic testing, warfarin, clopidogrel, personalized medicine


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy